QSAR and Molecular Modeling Studies in Heterocyclic Drugs I
Book w. online files/update
Series: Topics in Heterocyclic Chemistry; 3;
- Publisher's listprice EUR 213.99
-
90 774 Ft (86 451 Ft + 5% VAT)
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 8% (cc. 7 262 Ft off)
- Discounted price 83 512 Ft (79 535 Ft + 5% VAT)
90 774 Ft
Availability
Estimated delivery time: In stock at the publisher, but not at Prospero's office. Delivery time approx. 3-5 weeks.
Not in stock at Prospero.
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Edition number 2006
- Publisher Springer
- Date of Publication 22 June 2006
- Number of Volumes 1 pieces, Book w. online files / update
- ISBN 9783540333784
- Binding Hardback
- No. of pages278 pages
- Size 235x155 mm
- Weight 672 g
- Language English
- Illustrations XVI, 278 p. With online files/update. Halftones, black & white 0
Categories
Table of Contents:
P.R. Duchowicz, E.A. Castro, A.A. Toropov, E. Benfenati: Applications of Flexible Molecular Descriptors in the QSPR-QSAR Study of Heterocyclic Drugs.- S.C. Basak, D. Mills, B.D. Gute, R. Natarajan: Predicting Pharmacological and Toxicological Activity of Heterocyclic Compounds Using QSAR and Molecular Modeling.- M.N. Ponnuswamy, M.M. Gromiha, S.M. Malathy Sony, K. Saraboji: Conformational Aspects and Interaction Studies of Heterocyclic Drugs.- S. Khanna, R. Bahal, P.V. Bharatam: In silico Studies on PPARg Agonistic Heterocyclic Systems.- R. Garg, B. Bhhatarai: QSAR and Molecular Modeling Studies of HIV Protease Inhibitors.
More
